Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury
Status: | Completed |
---|---|
Conditions: | Hospital, Hospital, Hospital, Pulmonary |
Therapuetic Areas: | Pulmonary / Respiratory Diseases, Other |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/14/2019 |
Start Date: | April 2014 |
End Date: | January 8, 2018 |
Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ
failure as measured by Sequential Organ Failure Assessment (SOFA) score,
Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by
the oxygenation index and the VE40
Hypothesis 1C: Vitamin C infusion will attenuate biomarkers of inflammation (C-Reactive
Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar
epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a
fibrinolytic state (Tissue Factor Pathway Inhibitor).
failure as measured by Sequential Organ Failure Assessment (SOFA) score,
Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by
the oxygenation index and the VE40
Hypothesis 1C: Vitamin C infusion will attenuate biomarkers of inflammation (C-Reactive
Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar
epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a
fibrinolytic state (Tissue Factor Pathway Inhibitor).
Inclusion Criteria:
- Patients must have suspected or proven infection, and meet 2 out of 4 of the criteria
for Systemic Inflammatory Response (SIRS) due to infection, and be accompanied by at
least 1 criterion for sepsis-induced organ dysfunction, and meet all 5 criteria for
Acute Respiratory Distress Syndrome (ARDS).
- Suspected or proven infection: (e.g., thorax, urinary tract, abdomen, skin, sinuses,
central venous catheters, and central nervous system, see Appendix A).
- The presence of a systemic inflammatory response: Defined as: fever: >38ºC (any route)
or hypothermia: <36ºC (core temp only), tachycardia: heart rate > 90 beats/min or
receiving medications that slow heart rate or paced rhythm, leukocytosis: >12,000
WBC/µL or leukopenia: <4,000 WBC/µL or >10% band forms. Respiratory rate > 20 breaths
per minute or PaCO2 < 32 or invasive mechanical ventilation.
- The presence of sepsis associated organ dysfunction: (any of the following thought to
be due to infection)
- Sepsis associated hypotension (systolic blood pressure (SBP) < 90 mm Hg or an SBP
decrease > 40 mm Hg unexplained by other causes or use of vasopressors for blood
pressure support (epinephrine, norepinephrine, dopamine =/> 5mcg, phenylephrine,
vasopressin)
- Arterial hypoxemia (PaO2/FiO2 < 300) or supplemental O2 > 6LPM.
- Lactate > upper limits of normal laboratory results
- Urine output < 0.5 ml/kg/hour for > two hours despite adequate fluid resuscitation
- Platelet count < 100,000 per mcL
- Coagulopathy (INR > 1.5)
- Bilirubin > 2 mg/dL
- Glasgow Coma Scale < 11 or a positive CAM ICU score
- ARDS characterized by all the following criteria
- Lung injury of acute onset, within 1 week of an apparent clinical insult and with
progression of respiratory symptoms
- Bilateral opacities on chest imaging not explained by other pulmonary pathology (e.g.
pleural effusions, lung collapse, or nodules)
- Respiratory failure not explained by heart failure or volume overload
- Decreased arterial PaO2/FiO2 ratio ≤ 300 mm Hg
- Minimum PEEP of 5 cmH2O (may be delivered noninvasely with CPAP to diagnose mild ARDS
Exclusion Criteria:
- Known allergy to Vitamin C
- inability to obtain consent;
- age < 18 years;
- No indwelling venous or arterial catheter in patients requiring insulin in a manner
that requires glucose being checked more than twice daily (e.g. continuous infusion,
sliding scale);
- presence of diabetic ketoacidosis;
- more than 48 hrs since meeting ARDS criteria;
- patient or surrogate or physician not committed to full support (not excluded if
patient would receive all supportive care except for cardiac resuscitation);
- pregnancy or breast feeding,
- moribund patient not expected to survive 24 hours;
- home mechanical ventilation (via tracheotomy or noninvasive) except for CPAP/BIPAP
used only for sleep-disordered breathing;
- home O2 > 2LPM, except for with CPAP/BIPAP
- diffuse alveolar hemorrhage (vasculitis);
- interstitial lung disease requiring continuous home oxygen therapy;
- Active kidney stone
- Non English speaking;
- Ward of the state (inmate, other)
We found this trial at
5
sites
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Duncan Hite, MD
Phone: 216-445-3098
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
Atlanta, Georgia
Principal Investigator: Greg Martin, MD, MSc
Phone: 404-616-0148
Click here to add this to my saved trials
9200 W Wisconsin Ave
Milwaukee, Wisconsin 53226
Milwaukee, Wisconsin 53226
(414) 805-3666
Principal Investigator: Jonathon Truwit, MD
Froedtert and the Medical College of Wisconsin Froedtert Health combines with the Medical College of...
Click here to add this to my saved trials
Richmond, Virginia 23298
Principal Investigator: Alpha (Berry) Fowler, MD
Phone: 804-628-5710
Click here to add this to my saved trials